Exploratory analysis revealed inferior DFS in epidermal growth factor receptor (EGFR)-mutated non-Sq patients, though overall survival remained favorable with subsequent tyrosine kinase inhibitor therapy.<h4>Conclusion</h4>Histology-based induction CRT followed by surgery demonstrated feasibility and favorable outcomes, particularly for Sq and EGFR-negative non-Sq NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.